{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:10:00Z","timestamp":1768360200463,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"DOI":"10.7759\/cureus.101460","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:51:31Z","timestamp":1768333891000},"source":"Crossref","is-referenced-by-count":0,"title":["Acute Kidney Injury and Electrolyte Disorders Following Chimeric Antigen Receptor T-cell (CAR T-cell) Therapy in Adults With Hematologic Malignancies: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Omar A","family":"AlShammari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Alwadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Abuqurayn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebtesam","family":"AlMadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"AlBtoosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid I","family":"AlMatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadel","family":"Alrowaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: A race to revolutionize cancer therapy","volume":"46","author":"Subklewe M","year":"2019","unstructured":"Subklewe M, von Bergwelt-Baildon M, Humpe A. Chimeric antigen receptor T cells: A race to revolutionize cancer therapy. Transfus Med Hemother. 2019, 46:15-24. 10.1159\/000496870","journal-title":"Transfus Med Hemother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra A","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023, 14:1188049. 10.3389\/fimmu.2023.1188049","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al.. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018, 378:439-448. 10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy M","year":"2022","unstructured":"Elsawy M, Chavez JC, Avivi I, et al.. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022, 140:2248-2260. 10.1182\/blood.2022015478","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al.. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017, 377:2531-2544. 10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al.. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019, 380:45-56. 10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje N","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al.. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019, 380:1726-1737. 10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park JH","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al.. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018, 378:449-459. 10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude SL","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al.. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014, 371:1507-1517. 10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0615-5","article-title":"CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives","volume":"33","author":"Mohty M","year":"2019","unstructured":"Mohty M, Gautier J, Malard F, et al.. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019, 33:2767-2778. 10.1038\/s41375-019-0615-5","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero P","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al.. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023, 388:1002-1014. 10.1056\/NEJMoa2213614","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang JY","year":"2023","unstructured":"Wang JY, Wang L. CAR-T cell therapy: where are we now, and where are we heading?. Blood Sci. 2023, 5:237-248. 10.1097\/BS9.0000000000000173","journal-title":"Blood Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00982-8","article-title":"Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies","volume":"30","author":"Yang C","year":"2023","unstructured":"Yang C, Nguyen J, Yen Y. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. J Biomed Sci. 2023, 30:89. 10.1186\/s12929-023-00982-8","journal-title":"J Biomed Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.03.007","article-title":"Nephrotoxicity in CAR-T cell therapy","volume":"31","author":"Sadowski K","year":"2025","unstructured":"Sadowski K, Ploch W, Downar A, et al.. Nephrotoxicity in CAR-T cell therapy. Transplant Cell Ther. 2025, 31:407-418. 10.1016\/j.jtct.2025.03.007","journal-title":"Transplant Cell Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui N","year":"2022","unstructured":"Farooqui N, Sy-Go JP, Miao J, et al.. Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy. Mayo Clin Proc. 2022, 97:1294-1304. 10.1016\/j.mayocp.2022.05.018","journal-title":"Mayo Clin Proc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know","volume":"13","author":"Jhaveri KD","year":"2018","unstructured":"Jhaveri KD, Rosner MH. Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know. Clin J Am Soc Nephrol. 2018, 13:796-798. 10.2215\/CJN.12871117","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta S","year":"2020","unstructured":"Gupta S, Seethapathy H, Strohbehn IA, et al.. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020, 76:63-71. 10.1053\/j.ajkd.2019.10.011","journal-title":"Am J Kidney Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu SS","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al.. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018, 15:47-62. 10.1038\/nrclinonc.2017.148","journal-title":"Nat Rev Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae027","article-title":"Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies","volume":"17","author":"Le\u00f3n-Rom\u00e1n J","year":"2024","unstructured":"Le\u00f3n-Rom\u00e1n J, Iacoboni G, Bermejo S, et al.. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies. Clin Kidney J. 2024, 17:sfae027. 10.1093\/ckj\/sfae027","journal-title":"Clin Kidney J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood AC","year":"2022","unstructured":"Wood AC, Perez AP, Arciola B, et al.. Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis. Transplant Cell Ther. 2022, 28:829.e1-829.e8. 10.1016\/j.jtct.2022.09.009","journal-title":"Transplant Cell Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.007","article-title":"Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-cell therapy in lymphoma patients","volume":"22","author":"Ahmed G","year":"2022","unstructured":"Ahmed G, Bhasin-Chhabra B, Szabo A, et al.. Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-cell therapy in lymphoma patients. Clin Lymphoma Myeloma Leuk. 2022, 22:863-868. 10.1016\/j.clml.2022.07.007","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf270","article-title":"Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction","volume":"18","author":"Moncho-Franc\u00e9s F","year":"2025","unstructured":"Moncho-Franc\u00e9s F, Hernani R, Juan-Garc\u00eda I, et al.. Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction. Clin Kidney J. 2025, 18:sfaf270. 10.1093\/ckj\/sfaf270","journal-title":"Clin Kidney J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2021.03.008","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"27","author":"Gutgarts V","year":"2021","unstructured":"Gutgarts V, Jain T, Zheng J, et al.. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Transplant Cell Ther. 2021, 27:1649-1656. 10.1016\/j.bbmt.2021.03.008","journal-title":"Transplant Cell Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77720-z","article-title":"Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes","volume":"14","author":"Russo E","year":"2024","unstructured":"Russo E, Gambella M, Raiola AM, et al.. Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes. Sci Rep. 2024, 14:26886. 10.1038\/s41598-024-77720-z","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011422","article-title":"Acute kidney injury after CAR-T cell therapy: incidence, risk factors, and impact on outcomes","volume":"8","author":"Vincendeau M","year":"2024","unstructured":"Vincendeau M, Pallet N, Joly F, et al.. Acute kidney injury after CAR-T cell therapy: incidence, risk factors, and impact on outcomes. Blood Adv. 2024, 8:2245-2256. 10.1182\/bloodadvances.2023011422","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452294-acute-kidney-injury-and-electrolyte-disorders-following-chimeric-antigen-receptor-t-cell-car-t-cell-therapy-in-adults-with-hematologic-malignancies-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:51:32Z","timestamp":1768333892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452294-acute-kidney-injury-and-electrolyte-disorders-following-chimeric-antigen-receptor-t-cell-car-t-cell-therapy-in-adults-with-hematologic-malignancies-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.101460","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}